Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the ...

Cordycepin, derived from fungi, shows promise in cancer therapy by inhibiting growth factor signaling pathways critical for ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic ...

Cancer is thought to be the second most prevalent and leading cause of mortality worldwide, affecting both men and women among other chronic diseases. While there are several treatment options ...

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

Kura Oncology (KURA) reported preclinical data supporting the development of the Company’s menin inhibitor, ziftomenib, for the treatment ...

effectively silencing both the ERK and AKT/mTOR signaling pathways and driving robust cell cycle arrest and apoptosis. Given that imatinib is well established as the frontline standard of care in ...